Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
It remains under investigation in clinical trials registered on ClinicalTrials.gov and the EU Clinical Trials Register, and is not licensed for prescription or self-administration outside of formally approved research settings
GIP enhances insulin secretion in a glucose-dependent manner, meaning it boosts insulin release when blood sugar is elevated but does not push insulin levels dangerously low when blood sugar is normal
Possible Risks Potential concerns associated with research peptides may include hormonal effects, unexpected tissue responses, contamination, incorrect dosing, and unknown long-term biological impact
5-Amino-1MQ is engineered to target one specific enzyme, NNMT, without disrupting other essential processes
